Yunxia Tao

Yunxia Tao

Auto-generated profile, based on publicly available information

Yunxia Tao

Department of Oncology, The Affiliated Hospital of Xuzhou Medical University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
XQXiaoyan Qian
Xiaoyan Qian
HCHaizhu Chen
Haizhu Chen
YTYunxia Tao
Yunxia Tao
Background: Optimal biomarkers to select patients who will benefit most from immunotherapy remain lacking in nasopharyngeal cancer (NPC). This systematic review and meta-analysis aimed to evaluate the association between various biomarkers and clinical outcomes in NPC patients treated with immune checkpoint inhibitors (ICIs).Methods: Systematic searches of PubMed, Embase, Cochrane Library, and Web of Science databases were performed up to October 2022. Studies evaluating the association between biomarkers and intended outcomes of ICIs were included. The pooled odds ratio (OR) and hazard ratio (HR) with 95% confidence intervals (CIs) were calculated, respectively, for the objective response rate (ORR) and progression-free survival (PFS) under fixed or random-effect models.Results: A total of 15 studies involving 1,407 patients were included. The pooled analysis indicated that NPC patients with lower plasma Epstein-Barr virus (EBV) DNA level at baseline (OR = 2.14, 95% CI: 1.46-3.14, P < 0.001), decreased EBV DNA load during immunotherapy (OR = 4.57, 95% CI: 2.24-9.34, P = 0.002) and higher programmed cell death-ligand 1 (PD-L1) expression (OR = 2.35, 95% CI: 1.36-4.09, P = 0.002) had superior ORR than the counterparts. No significant differences of ORR were observed between positive PD-L1 expression and negative PD-L1 expression (OR = 1.50, 95% CI: 0.92-2.45, P = 0.104), as well as higher tumor mutation burden (TMB) and lower TMB (OR = 1.62, 95% CI: 0.41-6.44, P = 0.494). Patients with lower plasma EBV DNA level at baseline obtained a significant benefit on PFS than those with higher plasma EBV DNA level (HR = 0.52, 95% CI: 0.42-0.63, P < 0.001). There were no differences in PFS between decreased EBV DNA load and increased EBV DNA load during immunotherapy (HR = 0.51, 95% CI: 0.22-1.17, P = 0.109), higher PD-L1 expression and lower PD-L1 expression (HR = 0.65, 95% CI: 0.42-1.01, P = 0.054), positive PD-L1 expression and negative PD-L1 expression (HR = 0.90, 95% CI: 0.64-1.26, P = 0.531), lower TMB and higher TMB (HR = 0.84, 95% CI: 0.51-1.38, P = 0.684).Conclusion: Lower baseline plasma EBV DNA level, decreased plasma EBV DNA during immunotherapy, and higher PD-L1 expression are reliable biomarkers predicting better response to ICIs treatment. Lower baseline plasma EBV DNA level was also associated with longer PFS. It is warranted to further explore and better illuminate the utility of these biomarkers in future clinical trials and real-world practice.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022324434.

22 December 2022 in Current Medical Science
Verified
Journal Article
Closed access
PDF file
HCHaizhu Chen
Haizhu Chen
YTYun-Xia Tao
Yun-Xia Tao
YZYu Zhou
Yu Zhou
QZQiao-Feng Zhong
Qiao-Feng Zhong
LZLi-Qiang Zhou
Li-Qiang Zhou
YSYuan-kai Shi
Yuan-kai Shi

7 August 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SMShuai Mei
Shuai Mei
XQXiaoyan Qian
Xiaoyan Qian
HCHaizhu Chen
Haizhu Chen
XZXue Zhao
Xue Zhao
YLYuqi Li
Yuqi Li
YTYunxia Tao
Yunxia Tao
Background: Despite advances in immune checkpoint inhibitors (ICIs), the prognosis of patients with head and neck squamous cell carcinoma (HNSCC) remains poor, and reliable biomarkers for predicting clinical outcomes are still lacking. CD161, a lectin-like receptor expressed on multiple T-cell subsets, has been reported to inhibit T-cell cytotoxicity; however, its prognostic and immunological significance in HNSCC remains unclear. Methods: We analyzed transcriptomic data from the HNSCC cohort in the TCGA database and four GEO datasets (GSE6631, GSE102349, GSE159067, and GSE103322) to evaluate CD161 expression, its prognostic significance, and its association with immune infiltration and functional pathways. Single-cell RNA sequencing data were used to identify CD161-expressing cell subsets. Differential expression was further validated by immunohistochemistry (IHC) in 20 paired HNSCC and adjacent normal tissues. The association between CD161 expression and immunotherapy response was additionally assessed in an independent cohort of 33 ICI-treated patients. Results: CD161 expression was significantly lower in HNSCC tissues than in normal tissues in the TCGA cohort and the GSE6631 dataset, which was further confirmed by IHC analysis. High CD161 expression was associated with a favorable prognosis, with longer overall survival (OS) and disease-specific survival (DSS), and remained an independent protective factor in multivariate analysis (OS: hazard ratio [HR] = 0.92, 95% confidence interval [CI]: 0.86–0.99, p = 0.019; DSS: HR = 0.86, 95% CI: 0.78–0.96, p = 0.008). CD161 expression correlated with infiltration of CD8 + T cells and regulatory T cells, as well as with multiple immune checkpoint molecules, including CD27, TIGIT, BTLA, and PD-1. Single-cell analysis further localized CD161 predominantly to CD4 + T cells. In the GSE159067 dataset, high CD161 expression was associated with longer progression-free survival and overall survival. In our ICI-treated cohort, high CD161 expression correlated with longer PFS and higher objective response rate. Conclusion: CD161 is downregulated in HNSCC. Higher CD161 expression is associated with favorable prognosis and an immune-inflamed tumor microenvironment, and may predict response to ICI-containing therapy. These findings suggest that CD161 has potential as a prognostic biomarker and may help characterize tumor–immune interactions in HNSCC.